Details for New Drug Application (NDA): 022417

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

NDA 022417 describes NORVIR, which is a drug marketed by Abbott, Abbvie, and Abbvie Inc, and is included in five NDAs. It is available from two suppliers. Additional details are available on the NORVIR profile page.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ritonavir profile page.

Summary for 022417

Tradename:	NORVIR
Applicant:	Abbvie
Ingredient:	ritonavir
Patents:	0
Formulation / Manufacturing:	see details

Pharmacology for NDA: 022417

Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors P-Glycoprotein Inhibitors UDP Glucuronosyltransferases Inducers

Medical Subject Heading (MeSH) Categories for 022417

Cytochrome P-450 CYP3A Inhibitors
HIV Protease Inhibitors

Suppliers and Packaging for NDA: 022417

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NORVIR	ritonavir	TABLET;ORAL	022417	NDA	AbbVie Inc.	0074-2340	0074-2340-30	30 TABLET, FILM COATED in 1 BOTTLE (0074-2340-30)
NORVIR	ritonavir	TABLET;ORAL	022417	NDA	AbbVie Inc.	0074-3333	0074-3333-30	30 TABLET, FILM COATED in 1 BOTTLE (0074-3333-30)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	100MG
Approval Date:	Feb 10, 2010	TE:	AB	RLD:	Yes

Expired US Patents for NDA 022417

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010	⤷ Try a Trial	⤷ Try a Trial
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010	⤷ Try a Trial	⤷ Try a Trial
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010	⤷ Try a Trial	⤷ Try a Trial
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010	⤷ Try a Trial	⤷ Try a Trial
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010	⤷ Try a Trial	⤷ Try a Trial
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010	⤷ Try a Trial	⤷ Try a Trial
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.